AR and prostate cancer: In early FDHT-PET imaging studies, a circulating lipophilic but somewhat more polar radiolabeled metabolite was noted [115], and although it did not bind to AR and was not taken up by prostate cancer lesions, it made accurate measurement of blood levels of FDHT for pharmacokinetic modeling more difficult [116].